A systematic review of current studies in patients with familial hypercholesterolemia by use of national familial hypercholesterolemia registries

Current Opinion in Lipidology

Volumn 27, Issue 4, 2016, Pages 388-397

  Mundal, Liv ^a   Retterstl, Kjetil ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

cardiovascular disease; familial hypercholesterolemia; morbidity; mortality; registry studies

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; EARLY DIAGNOSIS; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; MORBIDITY; MORTALITY; POPULATION; PREVALENCE; PRIORITY JOURNAL; REGISTER; REVIEW; SYSTEMATIC REVIEW;

HUMANS; HYPERLIPOPROTEINEMIA TYPE II; REGISTRIES;

EID: 84963649271     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000300     Document Type: Review

References (34)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Baudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease. New York, NY: McGraw-Hill; 2001. pp. 2863-2913.
2. Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, et al. Familial hypercholesterolaemia: A global call to arms. Atherosclerosis 2015; 243:257-259.
3. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146-2157.
4. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36:560-565.
5. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173:55-68.
6. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478a-90a.
7. Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature 2015; 518:102-106.
8. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337:a1095.
9. Johansen D, Bogsrud MP, Holven KB. Nasjonal kompetansetjeneste for familiær hyperkolesterolemi. NKTforFH virksomhetsplan 2015; www. oslouniversitetssykehus. no/omoss-/avdelinger-/nasjonal-kompetansetjenestefor-barn-og-voksne-med-famili%c3%a6r-hyperkolesterolemi-og-andre-arveli ge-dyslipidemier-/Documents/NKTforFH%20virksomhetsplan. pdf [Accessed 20 December 2015]
10. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376:1670-1681.
11. Mabuchi H, Miyamoto S, Ueda K, et al. Causes of death in patients with familial hypercholesterolemia. Atherosclerosis 1986; 61:1-6.
12. Group SSCobotSBR. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303:893-896.
13. Group SSCobotSBR. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999; 142:105-112.
14. Neil HA, Hammond T, Huxley R, et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000; 321:148.
15. Sijbrands EJ, Westendorp RG, Paola Lombardi M, et al. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 2000; 149:421-425.
16. Sijbrands EJ, Westendorp RG, Defesche JC, et al. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001; 322:1019-1023.
17. Huxley RR, Hawkins MH, Humphries SE, et al. Risk of fatal stroke in patients with treated familial hypercholesterolemia: A prospective registry study. Stroke 2003; 34:22-25.
18. Neil HA, Huxley RR, Hawkins MM, et al. Comparison of the risk of fatal coronary heart disease in treated xanthomatous and nonxanthomatous heterozygous familial hypercholesterolaemia: A prospective registry study. Atherosclerosis 2003; 170:73-78.
19. de Sauvage Nolting PR, Defesche JC, et al. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003; 253:161-168.
20. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004; 256:482-490.
21. Mohrschladt MF, Westendorp RG, Gevers Leuven JA, et al. Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 2004; 172:329-335.
22. Neil HA, Hawkins MM, Durrington PN, et al. Noncoronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: A prospective registry study. Atherosclerosis 2005; 179:293-297.
23. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J 2008; 29:2625-2633.
24. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ 2008; 337:a2423.
25. Yamashita S, Hbujo H, Arai H, et al. Long-term probucol treatment prevents secondary cardiovascular events: A cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008; 15:292-303.
26. Alonso R, Mata N, Castillo S, et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008; 200:315-321.
27. Versmissen J, Botden IP, Huijgen R, et al. Maternal inheritance of familial hypercholesterolemia caused by the V408M low-density lipoprotein receptor mutation increases mortality. Atherosclerosis 2011; 219:690-693.
28. Toleikyte I, Retterstol K, Leren TP, et al. Pregnancy outcomes in familial hypercholesterolemia: A registry-based study. Circulation 2011; 124:1606-1614.
29. Mata N, Alonso R, Badimon L, Padro T, et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis 2011; 10:94.
30. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy. Circulation 2011; 124:2202-2207.
31. Besseling J, Kindt I, Hof M, et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14, 000 mutation carriers. Atherosclerosis 2014; 233:219-223.
32. Mundal L, Sarancic M, Ose L, et al. Mortality among patients with familial hypercholesterolemia: A registry-based study in Norway. J Am Heart Assoc 2014; 3:e001236.
33. Krogh HW, Mundal L, Holven KB, et al. Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. Eur Heart J 2015. doi: 10. 1093/eurheartj/ehv602.
34. Hammond E, Watts GF, Rubinstein Y, et al. Role of international registries in enhancing the care of familial hypercholesterolaemia. Int J Evid Based Healthc 2013; 11:134-139.